GI | Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Colorectal, Gastric and Hepatocellular Cancer

2:00:52
 
Share
 

Manage episode 230301366 series 1464173
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Meet The Professors: Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Colorectal, Gastric and Hepatocellular Cancer. Proceedings from a CME symposium held at the 2019 Gastrointestinal Cancers Symposium. Featuring perspectives on the following topics and cases from Dr Ghassan Abou-Alfa, Dr Peter C Enzinger, Dr Tim Greten, Dr David H Ilson, Dr Wells A Messersmith and Prof Eric Van Cutsem:

Gastric and Gastroesophageal Cancer

  • Case (Dr Enzinger): A 72-year-old woman with metastatic squamous cell carcinoma of the esophagus and a high PD-L1 combined positive score (CPS) receives third-line pembrolizumab (00:00)
  • KEYNOTE-181: Results of a Phase III trial of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal carcinoma (4:34)
  • Sequencing anti-PD-1 checkpoint inhibitors for patients with metastatic HER2-negative gastric cancer and a PD-L1 CPS of 1 or higher (7:37)
  • Case (Dr Ilson): A 71-year-old man with microsatellite-stable gastroesophageal junction (GEJ) adenocarcinoma and a high PD-L1 CPS (11:57)
  • Research supporting the FDA approval of pembrolizumab for recurrent or advanced gastric or GEJ adenocarcinoma with a PD-L1 CPS of 1 or higher after 2 or more lines of chemotherapy (16:03)
  • Clinical implications of the negative Phase III KEYNOTE-061 trial of pembrolizumab versus paclitaxel for previously treated advanced gastric or GEJ cancer (17:26)
  • ATTRACTION-2: Results of a Phase III trial of nivolumab versus placebo for unresectable advanced or recurrent gastric or GEJ adenocarcinoma after at least 2 previous chemotherapy regimens (19:51)
  • Second-line therapy options for patients with metastatic microsatellite-stable gastric cancer who experience disease progression on first-line FOLFOX (20:51)
  • Results of the Phase III TAGS study: Efficacy, tolerability and potential clinical role of TAS-102 for patients with heavily pretreated metastatic gastric cancer (23:52)
  • INTEGRATE: Results of a Phase II trial of regorafenib for patients with refractory gastric cancer (28:03)
  • Select ongoing Phase III studies of other novel agents and strategies for metastatic gastric or GEJ cancer (30:30)
  • Approach to second-line therapy for patients with metastatic HER2-positive, microsatellite-stable gastric cancer who experience disease progression on FOLFOX/trastuzumab (33:24)
  • Case (Dr Enzinger): A man with moderately differentiated HER2-positive metastatic GEJ adenocarcinoma (35:18)
  • Case (Dr Ilson): A 67-year-old woman with proximal gastric adenocarcinoma receives neoadjuvant FOLFOX (37:54)

Hepatocellular Carcinoma (HCC)

  • Perspective on the recent advances in the treatment of HCC (42:10)
  • Selection of first-line therapy for patients with HCC (46:05)
  • Case (Dr Abou-Alfa): A 63-year-old man with a history of hepatitis C is diagnosed with HCC with metastasis to the bone (47:23)
  • Choice of lenvatinib versus sorafenib as first-line therapy (50:15)
  • Efficacy and tolerability of lenvatinib versus sorafenib as up-front therapy in the Phase III REFLECT trial (Study 304) (51:27)
  • Therapeutic options for patients with HCC in the second-line setting (54:00)
  • Results of the Phase III RESORCE trial of regorafenib for patients with unresectable HCC who experience disease progression on sorafenib (57:28)
  • Case (Dr Abou-Alfa): A 71-year-old man with Stage IV hepatitis C-related HCC requires a dose reduction with second-line cabozantinib (59:42)
  • Activity and side-effect profile of cabozantinib; results from the Phase III CELESTIAL trial of cabozantinib for patients with advanced HCC (1:00:59)
  • Case (Dr Greten): A 72-year-old man with a history of hepatitis B and high alpha-fetoprotein (AFP) receives ramucirumab after disease progression on sorafenib (1:03:09)
  • REACH-2: A Phase III study of ramucirumab as second-line treatment for patients with advanced HCC and elevated AFP after first-line sorafenib (1:04:05)
  • Case (Dr Greten): A 37-year-old man with HCC metastatic to the omentum achieves a pathologic complete response with durvalumab (1:07:21)
  • Role of molecular profiling for patients with HCC (1:11:18)
  • KEYNOTE-224: A Phase II study of pembrolizumab in patients with advanced HCC previously treated with sorafenib (1:13:4)
  • Activity of nivolumab in the Phase I/II CheckMate 040 study for patients with advanced HCC (1:15:47)
  • Response and tolerability of atezolizumab/bevacizumab for patients with advanced HCC on a Phase Ib trial (1:17:14)
  • Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 combinations in HCC (1:19:52)

Colorectal Cancer (CRC)

  • Treatment algorithm for metastatic CRC (mCRC) based on tumor sidedness and biomarker status (1:22:06)
  • Efficacy and tolerability of anti-EGFR antibodies (1:26:52)
  • Case (Prof Van Cutsem): A 59-year old woman with mCRC, a BRAF V600E mutation and microsatellite-stable disease receives cetuximab, encorafenib and binimetinib on the BEACON CRC trial after disease progression on FOLFOX/bevacizumab (1:31:07)
  • Management of mCRC with a BRAF V600E mutation (1:33:42)
  • Results of the SWOG S1406 trial of irinotecan and cetuximab with or without vemurafenib for mCRC with a BRAF mutation (1:37:13)
  • Efficacy and safety of encorafenib, binimetinib and cetuximab in the Phase III BEACON CRC study for patients with mCRC and a BRAF V600E mutation (1:38:35)
  • Case (Dr Messersmith): A 40-year old man with microsatellite instability (MSI)-high mCRC and Lynch syndrome achieves a near-complete response after receiving an anti-PD-L1 antibody on a clinical trial (1:40:16)
  • Role of checkpoint inhibitors for patients with MSI-high mCRC (1:41:42)
  • Efficacy of anti-PD-1/PD-L1 antibodies in patients with microsatellite-stable disease (1:45:40)
  • Ongoing Phase III trials evaluating immune checkpoint inhibitors for patients with MSI-high mCRC (1:47:55)
  • Case: A 56-year-old woman with mCRC and a KRAS exon 2 mutation receives regorafenib as third-line therapy (1:49:17)
  • ReDOS: Optimal dosing of regorafenib in refractory mCRC; REVERCE: Sequencing of regorafenib and cetuximab for previously treated mCRC (1:57:01)
  • Efficacy and safety of TAS-102 in mCRC (1:58:58)

Select publications

2183 episodes